A detailed history of Washington Trust Advisors, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Washington Trust Advisors, Inc. holds 187 shares of BMRN stock, worth $12,459. This represents 0.0% of its overall portfolio holdings.

Number of Shares
187
Previous 159 17.61%
Holding current value
$12,459
Previous $13,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$69.02 - $93.84 $1,932 - $2,627
28 Added 17.61%
187 $13,000
Q4 2023

Jan 18, 2024

BUY
$76.22 - $98.51 $3,125 - $4,038
41 Added 34.75%
159 $15,000
Q3 2023

Oct 18, 2023

BUY
$85.07 - $94.48 $1,786 - $1,984
21 Added 21.65%
118 $10,000
Q1 2023

May 04, 2023

SELL
$87.74 - $117.27 $4,650 - $6,215
-53 Reduced 35.33%
97 $9,000
Q4 2022

Feb 08, 2023

SELL
$80.93 - $108.63 $24,359 - $32,697
-301 Reduced 66.74%
150 $15,000
Q2 2022

Jul 25, 2022

BUY
$71.48 - $86.85 $5,861 - $7,121
82 Added 22.22%
451 $37,000
Q1 2022

May 05, 2022

SELL
$74.28 - $92.69 $19,684 - $24,562
-265 Reduced 41.8%
369 $29,000
Q4 2021

Feb 11, 2022

BUY
$71.72 - $91.47 $45,470 - $57,991
634 New
634 $56,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Washington Trust Advisors, Inc. Portfolio

Follow Washington Trust Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Washington Trust Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Washington Trust Advisors, Inc. with notifications on news.